2

Question 1

This drug receptor is usually inhibited rather than activated:
A. Regulatory protein
B. Enzyme
C. Transport protein
D. Structural protein

Answer 1

B. Enzyme

Question 2

Binding with these molecules will result to no detectable change in the function of the biologic system:
A. Effector
B.Receptor
C. Inert Binding site
D. Spare receptor

Answer 2

C. Inert Binding site

Question 3

Produces the full maximal effect when receptors are saturated:
A. Full agonist
B. Partial Agonist
C. Competitive Antagonist
D. Irreversible Antagonist

Answer 3

A. Full agonist

Question 4

Secondary messenger that mediate most hormonal response:
A. cAMP
B. Calcium
C. PIP
D. cGMP

Answer 4

A. cAMP

Question 5

The dose at which 50% of the test population exhibit unintended effects:
A. ED50
B. LD50
C. MD50
D. TD50

Answer 5

TD50

Question 6

Maximal efficacy & potency are derived from this
A. Graded dose-response relationship
B. Quantal dose-response relationship
C. Both
D. Neither

Answer 6

A. Graded dose-response relationship

Question 7

Decreased sensitivity acquired as a result of exposure to the drug
A. Idiosyncratic
B. Tolerance
C. Hyporeactive
D. Hypereactive

Answer 7

B. Tolerance

Question 8

Down regulation which varies the drug response is due to:
A. Variation in drug concentration
B. Alteration in endogenous ligands
C. Alteration in receptor
D. Changes in 2nd messenger

Answer 8

C. Alteration in receptor

Question 9

Measured with a graded dose-response curve but not with quantal dose-response curve
A. Maximal Efficacy
B. Potency
C. Clinical sensitivity
D. Tachyphylaxis

Answer 9

A. Maximal Efficacy

Question 10

Drug interaction wherein one drug enhances the effect of another by inhibiting its metabolizing enzyme
A. Additive
B. Antagonism
C. Synergistic
D. Potentation

Answer 10

D. Potentation

Question 11

Binds to the drug inhibited

Answer 11

Chemical Antagonst

Question 12

Binds to the drug receptor

Answer 12

Competitive Antagonist / Irreversible Antagonist

Question 13

Binds via covalent bonds

Answer 13

Irreversible Antagonist

Question 14

Utilizes another regulatory pathway

Answer 14

Physiologic Antagonist

Question 15

Receptor dimerization

Answer 15

Tyrosine kinase mediated

Question 16

Epinephrine

Answer 16

G-protein mediated

Question 17

Used by neurons in synapse

Answer 17

Ligand-gated Ion channel

Question 18

Increase cGMP phosphodiesterase

Answer 18

Gt1 , Gt2

Question 19

Increase phospholipase C

Answer 19

Gs

Question 20

Increase adenylyl cyclase

Answer 20

Gl1, Gl2, Gl3

Question 21

Decrease adenylyl cyclase

Answer 21

Gl1, Gl2, Gl3

Question 22

Opens cardiac K+channels

Answer 22

Gt1 , Gt2

Question 23

Most potent

Answer 23

drug A / B

Question 24

Most efficacious

Answer 24

drug D

Question 25

`Least potent

Answer 25

Drug D

Question 26

Least efficacious

Answer 26

drug A

Question 27

QUANTITATIVE RELATIONSHIP Shade A if 1>2 , B if 1<2, C if 1=2 With spare receptors 1. Kd 2. EC50

Answer 27

A. 1>2

Question 28

QUANTITATIVE RELATIONSHIP Shade A if 1>2 , B if 1<2, C if 1=2 Drug Affinity 1. Kd=10 2. Kd= 100

Answer 28

B. 1<2

Question 29

QUANTITATIVE RELATIONSHIP Shade A if 1>2 , B if 1<2, C if 1=2 Margin of safety 1. Therapeutic index=2 2. Therapeutic index = 50

Answer 29

C. 1=2

Question 30

VARIATION RELATIONSHIP Shade A if an increase in 1 is followed by an increase in 2 B if an increase in 1 is followed by a decrease in 2 C if an increase in 1 will not affect 2 1.ED50 2. Efficacy

Answer 30

B. increase in 1 is followed by a decrease in 2

Question 31

VARIATION RELATIONSHIP Shade A if an increase in 1 is followed by an increase in 2 B if an increase in 1 is followed by a decrease in 2 C if an increase in 1 will not affect 2 1. Irreversible antagonist 2. Emax

Answer 31

B. increase in 1 is followed by a decrease in 2

Question 32

VARIATION RELATIONSHIP Shade A if an increase in 1 is followed by an increase in 2 B if an increase in 1 is followed by a decrease in 2 C if an increase in 1 will not affect 2 1.EC50 2. Potency

Answer 32

C. an increase in 1 will not affect 2

Question 33

T or F LD50 is the median toxic dose and means that 50% of the individuals manifested the toxic effects.

Answer 33

FALSE

Question 34

T or F A very safe drug might be expected to have a very large toxic dose and a much larger effective dose.

Answer 34

FALSE

Question 35

T or F Drug interactions are expected to produce adverse effects.